Both Eidos Therapeutics Inc. (NASDAQ:EIDX) and ProQR Therapeutics N.V. (NASDAQ:PRQR) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eidos Therapeutics Inc.||26||0.00||N/A||-1.74||0.00|
|ProQR Therapeutics N.V.||12||0.00||N/A||-1.23||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 represents Eidos Therapeutics Inc. (NASDAQ:EIDX) and ProQR Therapeutics N.V. (NASDAQ:PRQR)’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eidos Therapeutics Inc.||0.00%||-22.6%||-21.7%|
|ProQR Therapeutics N.V.||0.00%||-53.9%||-43.8%|
The Current Ratio and Quick Ratio of Eidos Therapeutics Inc. are 19 and 19 respectively. Its competitor ProQR Therapeutics N.V.’s Current Ratio is 10.1 and its Quick Ratio is 10.1. Eidos Therapeutics Inc. can pay off short and long-term obligations better than ProQR Therapeutics N.V.
Eidos Therapeutics Inc. and ProQR Therapeutics N.V. Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Eidos Therapeutics Inc.||0||0||2||3.00|
|ProQR Therapeutics N.V.||0||0||1||3.00|
Eidos Therapeutics Inc.’s downside potential currently stands at -17.12% and an $31.33 average target price. Meanwhile, ProQR Therapeutics N.V.’s average target price is $20, while its potential upside is 123.71%. Based on the data shown earlier, ProQR Therapeutics N.V. is looking more favorable than Eidos Therapeutics Inc., analysts opinion.
Institutional and Insider Ownership
Institutional investors held 35.8% of Eidos Therapeutics Inc. shares and 68.5% of ProQR Therapeutics N.V. shares. About 1.3% of Eidos Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 20% of ProQR Therapeutics N.V.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Eidos Therapeutics Inc.||-15.13%||0.49%||31.27%||174.94%||87.46%||136.77%|
|ProQR Therapeutics N.V.||5.15%||-6.99%||-20.18%||-41.23%||32.03%||-44.36%|
For the past year Eidos Therapeutics Inc. has 136.77% stronger performance while ProQR Therapeutics N.V. has -44.36% weaker performance.
Eidos Therapeutics Inc. beats ProQR Therapeutics N.V. on 5 of the 7 factors.
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.